Skip to main content

Table 2 Characteristics of patients and interventions in included records

From: Tranexamic acid in hip and spine surgery for children with cerebral palsy — a PRISMA-compliant scoping review

Characteristic

Findings—spine (n = 41 studies)

Findings—hip (n = 12 studies)

Age (years)

Range of reported mean values = 9.9 to 41.4

Not reported = 6 (14.6%)

Range of mean values = 6.5 to 11.1

Not reported = 1 (8.3%)

Sex

Range of proportions (% female) = 38.6 to 89.2

Not reported = 12 (29.3%)

Range of proportions (% female) = 35.0 to 69.1

Not reported = 0

Functional level

GMFCS level = 2 studies (4.9%)

Wheelchair dependence = 1 study (2.4%)

Spastic quadriplegia (not further specified) = 1 study (2.4%)

SRS-24 = 1 study (2.4%)

Not reported = 36 (87.8%)

GMFCS level (range of proportions of patients in each category):

- GMFCS I = 1.3% to 3.2%

- GMFCS II = 4.0% to 31.3%

- GMFCS III = 11.1% to 38.5%

- GMFCS IV = 21.4% to 56.3%

- GMFCS V = 0 to 64.5%

Not reported = 4 (33.3%)

TXA dosing

Number of studies using bolus only = 1 (2.4%)

Number of studies using infusion only = 0

Number of studies using bolus and infusion = 23 (56.1%)

Range of bolus dose (mg/kg) = 5 to 100

Range of intraoperative infusion dose (mg/kg/h) = 1 to 10

Number of studies with unclear or insufficient reporting = 17 (41.5%)

Number of studies using bolus only = *3 (25.0%)

Number of studies using infusion only = 0

Number of studies using bolus and infusion = *7 (58.3%)

Range of bolus doses (mg/kg) = 10 to 50

Range of intraoperative infusion dose (mg/kg/h) = 1 to 10

Number of studies with unclear or insufficient reporting = 3 (25.0%)

  1. TXA given intravenously unless otherwise specified; GMFCS, Gross Motor Function Classification System; SRS-24, Scoliosis Research Society 24-item questionnaire; *one study included a bolus-only arm and a bolus + infusion arm